Note: Ingredients listed on restricted chemical lists
EC/CAS
9003-39-8
Name of the chemical
polyvinylpyrrolidone
Concentration
<1
EC/CAS
236-675-5/13463-67-7
Name of the chemical
Reaction mass of titanium dioxide and silver chloride
Concentration
<1 23-<25
General Information
Revision date
2021-07-29
Product name
TELZIR / LEXIVA TABLETS
Product Synonyms
LEXIVA 700 MG TABLETS (US) * TELZIR 700 MG TABLETS * FOSAMPRENAVIR CALCIUM 700
Emergency telephone
VERISK 3E GLOBAL INCIDENT RESPONSE
Icons in SDS
Company Information
company name
ViiV Healthcare Limited
e-mail address of the competent person responsible for the Safety Data Sheet
msds@gsk.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H351, H361, H362, H373
Hazard statements
Code
Statements
H351
Suspected of causing cancer
Section 2
2.1 Classification of the substance or mixture
The mixture has been assessed and/or tested for its physical, health and environmental hazards and the following classification applies.
EU Classification
Regulation (EC) No 1272/2008 as amended
Health hazards
Carcinogenicity Category 2 H351 - Suspected of causing cancer. Reproductive toxicity Category 2 H361 - Suspected of damaging fertility or the unborn child. Reproductive toxicity Effects on or via lactation H362 - May cause harm to breast-fed children. Specific target organ toxicity - repeated Category 2 (liver) H373 - May cause damage to exposure organs (liver) through prolonged or repeated exposure. Hazard summary Caution - Pharmaceutical agent. See section 11 of the SDS for additional information on health hazards.
2.2 Label elements
Label according to Regulation (EC) No. 1272/2008 as amended
Contains
FOSAMPRENAVIR CALCIUM, Titanium dioxide
Signal word
Warning
Hazard statements
H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child. H362 May cause harm to breast-fed children. H373 May cause damage to organs (liver) through prolonged or repeated exposure.
Prevention
P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust/fume/gas/mist/vapours/spray. P263 Avoid contact during pregnancy and while nursing. P264 Wash thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.
Response
P308 + P313 IF exposed or concerned: Get medical advice/attention.
Storage
P405 Store locked up.
Disposal
P501 Dispose of contents/container in accordance with local/regional/national/international regulations.
Supplemental label elements
18.065 % of the mixture consists of component(s) of unknown acute oral toxicity. 98.565 % of the mixture consists of component(s) of unknown acute dermal toxicity. 98.565 % of the mixture consists of component(s) of unknown acute hazards to the aquatic environment. 95.665 % of the mixture consists of component(s) of unknown long-term hazards to the aquatic environment.
2.3 Other hazards
Caution - Pharmaceutical agent. See section 11 of the SDS for additional information on health hazards.
